Core Viewpoint - Securities class action lawsuits have been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding the company's business practices and safety concerns during the specified Class Period [1][3]. Group 1: Allegations Against Hims & Hers - The complaints allege that Hims & Hers engaged in deceptive promotion and selling of illegitimate versions of Wegovy, which posed risks to patient safety [3]. - It is claimed that there was a substantial risk of termination of Hims & Hers' collaboration with Novo Nordisk due to these practices [3]. - The positive statements made by the company regarding its business and operations were deemed materially misleading and lacked a reasonable basis [3]. Group 2: Legal Process and Participation - Investors in Hims & Hers have until August 25, 2025, to seek appointment as lead plaintiff representatives in the class action [4]. - A lead plaintiff is typically the investor or small group of investors with the largest financial interest and who are representative of the class [4]. - Investors can choose to participate actively or remain absent from the proceedings without affecting their ability to share in any recovery [4]. Group 3: Firm Background - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions for victims of corporate misconduct [5]. - The firm aims to protect investors and consumers from fraud and negligence by businesses [5].

Group 1: Novo Nordisk - Novo Nordisk has faced challenges including a clinical setback for a weight management candidate and financial results that, while strong, did not meet higher market expectations [4][5] - The company's shares are down 18% year to date, significantly underperforming the S&P 500, but the stock may currently be undervalued [5] - Novo Nordisk's pipeline, particularly in diabetes and weight management, remains robust, with a phase 3 study for amycretin underway and regulatory approval requested for an oral version of semaglutide [6][7] - Financial performance is expected to remain strong due to continued revenue growth from Ozempic and Wegovy, with a forward price-to-earnings ratio of 16.9, comparable to the healthcare industry average of 16.5 [8] - Historically, Novo Nordisk has outpaced its peers in revenue and earnings growth, making its current stock levels attractive based on growth potential [9] Group 2: Regeneron Pharmaceuticals - Regeneron is experiencing biosimilar competition for Eylea, leading to a 19% decline in shares year to date, but the stock remains appealing [10] - The newer high-dose formulation of Eylea is gaining market share and is expected to grow further with label expansions [11] - Regeneron has a strong pipeline with new brand approvals, including Lynozyfic for cancer, and promising candidates like a gene therapy for genetic deafness [12] - Dupixent, Regeneron's key product for eczema, is performing well and has received important label expansions, ensuring continued growth [13] - The company is focused on returning capital to shareholders through dividends and a share-buyback program, suggesting potential long-term returns for investors [14]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk on April 29, 2025, to sell the weight loss drug Wegovy on its platform [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, claiming compliance with FDA regulations regarding the sale of compounded semaglutide [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement on June 23, 2025, that it was terminating the partnership due to Hims & Hers' deceptive practices, the company's stock price fell by $22.24 per share, a decline of over 34% [5].

Core Insights - The iREIT®+HOYA Capital investing group focuses on income-oriented alternatives such as REITs, BDCs, MLPs, and Preferreds, leveraging a team with over 100 years of combined experience [2] - Brad Thomas, a key figure in the group, has extensive real estate investing experience, having been involved in over $1 billion in commercial real estate transactions [3] Group 1 - iREIT® Tracker provides comprehensive data on over 250 tickers, including quality scores and buy/trim targets [1] - The team includes diverse professionals, such as a former hedge fund manager and a military veteran, enhancing the depth of analysis [2] Group 2 - Brad Thomas has been featured in major media outlets like Barron's and Bloomberg, indicating his influence and recognition in the real estate investment community [3]

Core Points - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. for alleged securities fraud occurring between April 29, 2025, and June 23, 2025 [1][2] - The lawsuit claims that Hims was involved in deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety and risked the termination of its collaboration with Novo Nordisk [2] - Investors affected by the alleged fraud have until August 25, 2025, to request to be appointed as lead plaintiff, with no out-of-pocket costs for class members to participate [3] Company Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4]

Core Viewpoint - Novo Nordisk announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending an update to the Alhemo® (concizumab) label to include treatment for severe haemophilia A and moderate or severe haemophilia B without inhibitors [1][4]. Company Overview - Novo Nordisk is a leading global healthcare company founded in 1923, headquartered in Denmark, focusing on chronic diseases, particularly diabetes, and employs approximately 77,400 people across 80 countries [9]. Product Information - Alhemo® (concizumab) is an anti-tissue factor pathway inhibitor designed to block a protein that prevents blood clotting, thus facilitating thrombin production to help clot blood and prevent bleeding [5]. - Currently, Alhemo® is approved in multiple countries, including Europe, the United States, India, Brazil, and Switzerland, for patients with haemophilia A and B with inhibitors, and in Japan and Australia for both with and without inhibitors [5]. Clinical Trial Results - The positive CHMP opinion is based on the phase 3 explorer8 trial, which demonstrated that Alhemo® prophylaxis led to an 86% reduction in treated spontaneous bleeds and a 79% reduction in traumatic bleeds for patients with haemophilia A and B without inhibitors, respectively [2][7]. - Patient-Reported Outcome (PRO) data indicated improvements in health-related quality of life and reduced treatment burden with Alhemo® compared to no prophylaxis, with 70.9% of respondents preferring Alhemo® over previous treatments [3]. Regulatory Expectations - Following the positive opinion from the CHMP, Novo Nordisk anticipates that the European Commission will approve the label update within approximately two months, making Alhemo® available to all patients aged 12 and older with severe haemophilia A and moderate or severe haemophilia B without inhibitors [4][7].

Core Insights - A leading Chinese drug developer, Jiangsu Hengrui Pharmaceuticals, is advancing in the weight-loss medication market with promising Phase Three trial results for its dual-acting obesity drug, HRS9531, which targets the same peptide receptors as Eli Lilly's tirzepatide [2][3][4] Company Developments - Hengrui Pharmaceuticals recently listed its shares in Hong Kong and has reported positive trial data for HRS9531, a dual-acting obesity drug [3][5] - The company plans to apply for domestic marketing approval for HRS9531 following successful Phase Three trial outcomes [4][6] - The trial involved 567 participants, with those receiving the drug achieving significant weight loss, including a mean weight loss of up to 17.7% and 88% of participants losing at least 5% of their weight [7][8] Market Context - The weight-loss medication market is highly competitive, with major players like Novo Nordisk and Eli Lilly leading the sector [12][17] - Hengrui Pharma's drug is positioned to compete with established products, as it targets GLP-1 and GIP receptors, similar to tirzepatide [10][15] - The market for weight-loss drugs in China is expanding rapidly, with over 200 pipelines currently in development [13] Financial Implications - Hengrui Pharma's stock has traded at a premium of approximately 10% over its Shanghai-listed shares, reflecting investor confidence in its potential [5] - The company has licensed rights to HRS9531 outside Greater China to Kailera Therapeutics, receiving $110 million in upfront payments and potential milestone payments totaling up to $5.725 billion based on sales [11] Competitive Landscape - The success of semaglutide has spurred a race for similar products, with Hengrui Pharma aiming to launch China's first independently developed GLP-1/GIP product [13][17] - Despite the dominance of established players, the high-growth market presents opportunities for new entrants like Hengrui Pharma [16][17]

Core Insights - Zacks Premium provides tools for investors to enhance their stock market engagement and confidence, including daily updates, research reports, and stock screens [1] Zacks Style Scores - Zacks Style Scores are indicators designed to help investors select stocks likely to outperform the market within 30 days, rated from A to F based on value, growth, and momentum [2] - The Value Score focuses on identifying undervalued stocks using financial ratios like P/E and Price/Sales [3] - The Growth Score assesses a company's financial health and future potential through earnings and sales projections [4] - The Momentum Score identifies optimal times to invest based on price trends and earnings estimate changes [5] - The VGM Score combines all three Style Scores, providing a comprehensive evaluation of stocks based on value, growth, and momentum [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to aid in portfolio building, with 1 (Strong Buy) stocks achieving an average annual return of +23.62% since 1988, significantly outperforming the S&P 500 [7] - There are over 800 stocks rated 1 or 2, making it essential to utilize Style Scores to narrow down choices [8] - For optimal returns, stocks should ideally have a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - The direction of earnings estimate revisions is crucial; stocks with lower ranks and declining forecasts pose higher risks despite good Style Scores [10] Company Spotlight: Novo Nordisk - Novo Nordisk, based in Denmark, is a leading global healthcare company specializing in diabetes care and other therapeutic areas [11] - Currently rated 3 (Hold) with a VGM Score of B, Novo Nordisk has a Momentum Style Score of B, with shares increasing by 4% over the past month [12] - Recent earnings estimates for fiscal 2025 have been revised upward, with the Zacks Consensus Estimate rising by $0.14 to $3.98 per share, indicating a stable earnings surprise of +0% [12]

Core Insights - First Principles Partners specializes in equity research focused on technology, innovation, and sustainability investment, utilizing a unique approach that breaks down complex problems to their basic elements [1] Group 1: Company Overview - First Principles Partners has a strong background in investment, private equity, and venture capital, demonstrating a proven track record of delivering strong returns [1] - The company emphasizes emerging technologies and sustainable investing, highlighting the intersection of innovation and finance [1] Group 2: Investment Philosophy - The "First Principles" approach allows the company to uncover overlooked investment opportunities by analyzing financial and technological aspects [1] - The company is committed to sharing insights with a wider audience and learning from fellow investors to drive positive change [1]

NEW YORK, July 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS).Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/hims-hers-health-inc-loss-submission-form/?id=157769&from=4CLASS PERIOD: April 29, ...